Equities

JG Chemicals Ltd

JGCHEM:NSI

JG Chemicals Ltd

Actions
Basic MaterialsChemicals
  • Price (INR)412.85
  • Today's Change-2.75 / -0.66%
  • Shares traded256.58k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 11:27 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

J.G.Chemicals Limited is engaged in the business of manufacturing of zinc oxide and allied product. The Company’s product caters to a spectrum of industrial applications, including in the rubber (tire and other rubber products), ceramics, paints and coatings, pharmaceuticals and cosmetics, electronics and batteries, agro-chemicals and fertilizers, specialty chemicals, lubricants, oil and gas and animal feed. The installed capacity of its Naidupeta Facility specified above, has recently been augmented by an additional 13,440 metric tons per annum (MTPA) for zinc oxide and 10,080 MTPA for zinc sulphate and other allied chemicals. It procures its raw materials from multiple domestic and global suppliers. Its primary raw materials are virgin zinc metal and Zinc Dross (which is a type of zinc scrap). It has three manufacturing facilities at Belur and Jangalpur, located in Kolkata district, West Bengal and at Naidupeta, located in Nellore district, Andhra Pradesh.

  • Revenue in INR (TTM)--
  • Net income in INR--
  • Incorporated2001
  • Employees56.00
  • Location
    JG Chemicals Ltd34A Metcalfe StreetKOLKATA 700091IndiaIND
  • Phone+91 3 344150100
  • Fax+91 3 340140199
  • Websitehttps://www.jgchem.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Jagsonpal Pharmaceuticals Ltd2.10bn203.13m10.71bn1.03k53.48--47.265.107.577.5778.03--------2,048,663.00--10.95--13.2956.4158.139.679.21--26.27--43.81-11.834.58-15.9425.50-35.6982.06
Bajaj Healthcare Ltd4.76bn-133.27m12.19bn944.00----82.842.56-4.82-10.30172.62--------5,041,608.00--7.67--14.1148.4333.26-2.807.99--1.74--4.90-26.695.04-122.55--15.08--
Bliss GVS Pharma Ltd7.94bn814.66m13.04bn831.0016.26--11.201.647.637.6374.93--------9,559,162.00--6.46--8.2251.8143.9111.249.92------7.922.48-3.036.49-9.42-8.33-12.94
Ngl Fine Chem Ltd3.58bn420.29m13.12bn390.0031.22--34.023.6668.0368.03580.00--------9,188,328.00--15.06--19.5852.0243.5311.7313.15--26.59--3.0621.7917.20101.5815.4714.490.00
Remus Pharmaceuticals Ltd450.27m85.03m14.21bn38.00150.8754.68158.1831.5515.9815.9890.2544.09------11,849,290.00--------52.39--18.88--1.35--0.2933--82.17--151.14------
Lincoln Pharmaceuticals Ltd5.92bn979.63m14.57bn1.70k14.87--13.342.4648.9148.91295.69--------3,483,600.00--13.95--16.5451.9250.6516.5414.71--60.93--3.4413.769.6627.9913.8821.543.71
Kopran Ltd6.37bn592.79m15.61bn358.0022.29--21.442.4514.5314.53150.01--------17,794,040.00--8.47--12.2336.0332.939.318.89--27.17--25.4111.5411.4287.1116.2312.53--
JG Chemicals Ltd-100.00bn-100.00bn16.17bn56.00-------------------------------------------------14.90---43.84------
Beta Drugs Ltd2.96bn364.37m16.48bn315.0045.2210.4935.655.5737.9037.90307.60163.431.314.514.17--16.1015.1023.9122.2338.7339.7712.3212.381.5117.810.0654--30.2135.0118.6235.29-10.89--
Zota Health Care Ltd1.98bn-242.34m16.59bn445.00----3,553.168.37-9.27-9.2776.32--------4,452,605.00---1.38---1.8549.8635.95-12.23-1.33---2.87----28.9616.08-148.54--39.850.00
Windlas Biotech Ltd6.61bn596.01m17.97bn1.15k30.14--23.632.7228.5228.52316.58--------5,730,702.00--------37.39--9.01----48.16----22.97--36.51------
Sigachi Industries Ltd4.10bn594.65m18.18bn991.0034.00--25.554.431.601.6010.97--------4,136,886.00--14.77--19.5752.3350.3014.4314.92--7.19--1.6132.0825.3431.3424.6470.35--
Hester Biosciences Ltd2.99bn193.56m20.17bn642.00101.92--53.286.7523.2623.26350.03--------4,656,698.00--6.15--7.6971.5266.647.3412.83--2.26--23.2714.4511.33-29.06-14.591.49-11.42
Panacea Biotec Ltd5.46bn-279.53m20.25bn1.15k----266.613.71-4.58-4.5889.84--------4,761,763.00--10.26--16.5360.2450.27-5.2024.87---17.30--0.0021.574.1396.47--74.65--
Syncom Formulations (India) Ltd2.91bn285.50m20.94bn802.0068.35--62.577.200.3260.3262.99--------3,626,019.00--7.50--10.2339.5334.109.829.38--7.67----17.457.1226.1317.95----
Data as of Sep 20 2024. Currency figures normalised to JG Chemicals Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

3.00%Per cent of shares held by top holders
HolderShares% Held
Carnelian Asset Management & Advisors Pvt Ltd.as of 30 Jun 2024694.64k1.77%
PineBridge Investments Asia Ltd.as of 30 Jun 2024480.86k1.23%
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.